BR0314657A - Inibidores de fusão de derivados de peptìdeo de infecção de hiv - Google Patents

Inibidores de fusão de derivados de peptìdeo de infecção de hiv

Info

Publication number
BR0314657A
BR0314657A BR0314657-0A BR0314657A BR0314657A BR 0314657 A BR0314657 A BR 0314657A BR 0314657 A BR0314657 A BR 0314657A BR 0314657 A BR0314657 A BR 0314657A
Authority
BR
Brazil
Prior art keywords
peptide derivative
hiv infection
fusion inhibitors
derivative fusion
inhibitors
Prior art date
Application number
BR0314657-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dong Xie
He Jiang
Original Assignee
Dong Xie
He Jiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Xie, He Jiang filed Critical Dong Xie
Publication of BR0314657A publication Critical patent/BR0314657A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16HIV-1 ; HIV-2
    • C07K14/162HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314657-0A 2002-09-24 2003-09-23 Inibidores de fusão de derivados de peptìdeo de infecção de hiv BR0314657A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24
PCT/US2003/029815 WO2004029201A2 (en) 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of hiv infection

Publications (1)

Publication Number Publication Date
BR0314657A true BR0314657A (pt) 2005-08-02

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314657-0A BR0314657A (pt) 2002-09-24 2003-09-23 Inibidores de fusão de derivados de peptìdeo de infecção de hiv

Country Status (15)

Country Link
US (3) US7575750B2 (https=)
EP (1) EP1542718B1 (https=)
JP (2) JP5385497B2 (https=)
CN (1) CN1327897C (https=)
AP (1) AP2203A (https=)
AU (2) AU2003275116A1 (https=)
BR (1) BR0314657A (https=)
CA (1) CA2500248C (https=)
CR (1) CR7806A (https=)
EA (1) EA007918B1 (https=)
ES (1) ES2558680T3 (https=)
IL (1) IL167527A (https=)
NZ (1) NZ539539A (https=)
WO (1) WO2004029201A2 (https=)
ZA (1) ZA200503118B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发(河北)有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
WO2020223906A1 (en) 2019-05-07 2020-11-12 Frontier Biotechnologies Inc. Stable albuvirtide compositions
WO2022003674A1 (en) * 2020-06-28 2022-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Neutrophil-binding peptides
CN115025218B (zh) * 2021-07-30 2025-03-28 前沿生物药业(南京)股份有限公司 联用治疗人类免疫缺陷病毒的活性组合及其应用
WO2024238349A1 (en) * 2023-05-12 2024-11-21 Frontier Medicines Corporation Identification and characterization of protein sites

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) * 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
AU723537B2 (en) * 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
EP1179012B2 (en) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection

Also Published As

Publication number Publication date
CA2500248A1 (en) 2004-04-08
ZA200503118B (en) 2006-11-29
JP2006505536A (ja) 2006-02-16
JP2010209097A (ja) 2010-09-24
WO2004029201A3 (en) 2004-08-12
CN1327897C (zh) 2007-07-25
CN1668330A (zh) 2005-09-14
AU2010200823B2 (en) 2011-12-15
US20110003735A1 (en) 2011-01-06
AU2010200823A1 (en) 2010-03-25
US8470527B2 (en) 2013-06-25
AU2003275116A1 (en) 2004-04-19
EP1542718B1 (en) 2015-11-11
EA007918B1 (ru) 2007-02-27
JP5385497B2 (ja) 2014-01-08
AP2203A (en) 2011-01-31
NZ539539A (en) 2006-11-30
CR7806A (es) 2007-09-07
WO2004029201A2 (en) 2004-04-08
IL167527A (en) 2013-12-31
US20050089840A1 (en) 2005-04-28
US20140187476A1 (en) 2014-07-03
ES2558680T3 (es) 2016-02-08
US7575750B2 (en) 2009-08-18
EP1542718A2 (en) 2005-06-22
AP2005003291A0 (en) 2005-06-30
CA2500248C (en) 2013-03-19
EP1542718A4 (en) 2011-04-06
EA200500533A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
DE60229677D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
BR0314657A (pt) Inibidores de fusão de derivados de peptìdeo de infecção de hiv
EA200401437A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
CY1107626T1 (el) Παραγωγα πυραζολιου για την θεραπεια του hiv
TR199903053T2 (xx) Benzimidazol t�revleri.
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
DK1401826T3 (da) Pyrazolderivater som inhibitorer for HIV-revers transcriptase
FR2792206B1 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
CA2195125A1 (en) Difluorostatone antiviral agents
WO2003100036A3 (fr) Sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih.
DK0859613T3 (da) Anvendelse af flupirtin til forebyggelse og behandling af sygdomme, som er forbundet med beskadigelse af det hæmopoietiske cellesystem
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
MXPA04004061A (es) Derivados de quinolina y piridina antiretrovirales.
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
HRP20030701A2 (en) Natural antibodies active against hiv virus
MX2024007429A (es) Terapias de combinacion para infecciones por vih y usos de las mismas.
EP1752469A3 (en) Long lasting fusion peptide inhibitors for HIV infection

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]